Griffin Asset Management Inc. Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Griffin Asset Management Inc. has acquired a new position in Structure Therapeutics Inc., purchasing 11,205 shares valued at approximately $232,000.
• Significant investment increases were noted from other institutional investors, including a 1,448.2% increase by the National Bank of Canada FI during the first quarter.
• Structure Therapeutics reported a quarterly loss of ($0.36) earnings per share, missing analysts' expectations by ($0.08).

Griffin Asset Management Inc. bought a new position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 11,205 shares of the company's stock, valued at approximately $232,000.

Other large investors have also added to or reduced their stakes in the company. National Bank of Canada FI grew its position in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after buying an additional 2,766 shares during the period. ANTIPODES PARTNERS Ltd grew its position in shares of Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after buying an additional 3,213 shares during the period. Signaturefd LLC grew its holdings in Structure Therapeutics by 6,550.0% in the second quarter. Signaturefd LLC now owns 6,650 shares of the company's stock worth $138,000 after purchasing an additional 6,550 shares during the period. Banque Pictet & Cie SA grew its holdings in Structure Therapeutics by 10.2% in the first quarter. Banque Pictet & Cie SA now owns 81,766 shares of the company's stock worth $1,415,000 after purchasing an additional 7,589 shares during the period. Finally, GAMMA Investing LLC grew its holdings in Structure Therapeutics by 663.8% in the first quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock worth $152,000 after purchasing an additional 7,627 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Stock Up 0.4%

Shares of NASDAQ GPCR opened at $30.19 on Tuesday. The stock's 50 day moving average price is $22.01 and its 200-day moving average price is $21.32. Structure Therapeutics Inc. Sponsored ADR has a twelve month low of $13.22 and a twelve month high of $42.57. The company has a market capitalization of $1.74 billion, a PE ratio of -28.75 and a beta of -1.65.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. Guggenheim reduced their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. HC Wainwright reduced their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. JMP Securities reduced their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research report on Thursday, August 7th. Finally, Lifesci Capital raised shares of Structure Therapeutics to a "strong-buy" rating in a research report on Monday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $68.67.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.